Guard Medical Announces the Enrollment of the First 5 Patients in the Post-market Study of Its NPseal
“The application of negative pressure wound therapy is simple. The dressing maintained negative pressure for the duration of therapy as prescribed by the study protocol,” stated Joongho Shin, MD, colon and rectal surgeon, Keck Medicine of USC, and principal investigator of the study.
“The first cases demonstrate fast application and easy activation of the NPsealTM,” stated Machiel van der Leest, CEO of Guard Medical. “This ease of use combined with its cost effectiveness makes prophylactic use of NPWT for closed surgical wounds possible.”
NPWT has been shown to reduce Surgical Site Infections (SSI) in a large number of peer reviewed articles but is in limited use due to its high cost and complexity. While being easy-to-use, NPsealTM delivers the same NPWT as current more expensive and complex NPWT devices.
Guard Medical Inc. (www.guard-medical.com), a privately-held company, is developing easy-to-use and cost-effective solutions that enables prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physician’s identification of unmet needs related to Surgical Site Infections (SSI). Current investors include Bpifrance and Matignon Investissement et Gestion.
Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.
Dr. Frederick Cornhill
Chief Scientific Officer, Guard Medical
Source: Guard Medical Inc.